In 2021, the world's two largest tobacco companies, BAT and Philip Morris International (PMI), invested a total of $1.15 billion in the research and development of risk-free alternatives to combustible cigarettes.
Hugo Tan, the head of scientific research for British American Tobacco in the Asia Pacific and Middle East regions, has stated that BAT invested $589 million last year in the development of new products. Tan told Arab News that the company is investing in heated tobacco and e-cigarette products in order to achieve its goal of ending combustible cigarette use. This goal has gained widespread acceptance and adoption in many countries, including the US, UK, Germany, France, and others.
PMI began researching smokeless products as early as 2008, and has since invested over 9 billion USD in this field. According to their website, PMI employs over 930 scientists, engineers, and technical staff dedicated to establishing scientific assessment capabilities. In 2021, PMI reported a total expenditure of 566 million USD on smokeless product research and development, a 14% increase from the 495 million USD spent in 2020.
In order to assess the potential risk reduction of our smoke-free products, we have developed a comprehensive scientific evaluation plan inspired by pharmaceutical industry standard practices and in line with evaluation guidelines provided by the FDA," said Ignacio Gonzalez Suarez, Head of Science Engagement for PMI in the Middle East and Africa.
I'm sorry, but there is no text provided for me to translate to standard journalistic English. Please provide a text for me to assist you better.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
